[논문]Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?

Park, Hyunkyung; Byun, Ja Min; Yoon, Sung-Soo; Koh, Youngil; Shin, Dong-Yeop; Hong, Junshik; Kim, Inho

doi:10.3390/jcm9082354

[해외논문] Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant? 원문보기

Journal of clinical medicine, v.9 no.8, 2020년, pp.2354 -

Park, Hyunkyung (Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul 07061, Korea) , Byun, Ja Min (spikenice@hanmail.net) , Yoon, Sung-Soo (Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Korea) , Koh, Youngil (go01@snu.ac.kr (Y.K.)) , Shin, Dong-Yeop (stephano.dyshin@gmail.com (D.-Y.S.)) , Hong, Junshik (alertjun@hanmail.net (J.H.)) , Kim, Inho (kim_dajung@hanmail.net (I.K.))

Abstract ▼ AI-Helper

Background: Despite offering an attractive option, the role of allogeneic stem cell transplantation (alloSCT) for treatment of multiple myeloma (MM) remains unclear. Methods: Recognizing the paucity of data in the Asian population, we retrospectively evaluated the outcomes of 24 patients (median age 52) undergoing alloSCT between April 2003 and November 2017. Results: The median time from diagnosis to alloSCT was 39.4 months. The majority of the patients (70.8%) underwent alloSCT followed by reduced intensity conditioning regimens after a median of five lines of therapy. Among 24 patients, 15 patients (62.5%) had a high-risk MM feature. The two-year relapse-free survival (RFS) and overall survival (OS) of the total patients were 29.2 ± 9.3% and 44.3 ± 10.3%, respectively. Patients who were treated with less chemotherapy lines (<5) before alloSCT had a prolonged RFS and OS. All patients (seven patients) who received a myeloablative conditioning regimen had high-risk features, but two out of seven patients showed long-term survival without lasting sequelae. Nine patients (37.5%) experienced non-relapse mortality (NRM) within one year after alloSCT (the one-year cumulative incidence of NRM was 38.3 ± 10.1%). Conclusion: AlloSCT can still be implemented as effective salvage option in the treatment of relapsed/refractory high-risk MM. The optimal timing of alloSCT remains to be determined.

Keyword

참고문헌 (34)

1. Stewart A.K. Rajkumar S.V. Dimopoulos M.A. Masszi T. ？pika I. Oriol A. Hajek R. Rosinol L. Siegel D.S. Mihaylov G.G. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma N. Engl. J. Med. 2015 372 142 152 10.1056/NEJMoa1411321 25482145

상세보기
2. Siegel D.S. Dimopoulos M.A. Ludwig H. Facon T. Goldschmidt H. Jakubowiak A. San-Miguel J. Obreja M. Blaedel J. Stewart A.K. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma J. Clin. Oncol. 2018 36 728 734 10.1200/JCO.2017.76.5032 29341834

상세보기
3. Suzuki K. Dimopoulos M.A. Takezako N. Okamoto S. Shinagawa A. Matsumoto M. Kosugi H. Yoon S.S. Huang S.Y. Qin X. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: Subgroup analyses of the phase 3 POLLUX study Blood Cancer J. 2018 8 41 10.1038/s41408-018-0071-x 29712896

상세보기
4. Mateos M.V. Spencer A. Nooka A.K. Pour L. Weisel K. Cavo M. Laubach J.P. Cook G. Iida S. Benboubker L. Daratumumab-Based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: Subgroup analysis of the phase 3 CASTOR and POLLUX studies Haematologica 2020 105 468 477 10.3324/haematol.2019.217448 31221782

상세보기
5. Dimopoulos M.A. Oriol A. Nahi H. San-Miguel J. Bahlis N.J. Usmani S.Z. Rabin N. Orlowski R.Z. Komarnicki M. Suzuki K. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma N. Engl. J. Med. 2016 375 1319 1331 10.1056/NEJMoa1607751 27705267

상세보기
6. Zagouri F. Terpos E. Kastritis E. Dimopoulos M.A. Emerging antibodies for the treatment of multiple myeloma Expert Opin. Emerg. Drugs 2016 21 225 237 10.1080/14728214.2016.1186644 27195659

상세보기
7. Tricot G. Vesole D.H. Jagannath S. Hilton J. Munshi N. Barlogie B. Graft-Versus-Myeloma effect: Proof of principle Blood 1996 87 1196 1198 10.1182/blood.V87.3.1196.bloodjournal8731196 8562947

상세보기
8. Kim H.T. Armand P. Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: The cost of freedom Biol. Blood Marrow Transplant. 2013 19 860 866 10.1016/j.bbmt.2013.01.003 23305679

상세보기
9. Giralt S. Garderet L. Durie B. Cook G. Gahrton G. Bruno B. Hari P. Lokhorst H. McCarthy P. Krishnan A. American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials network, and international myeloma working group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma Biol. Blood Marrow Transplant. 2015 21 2039 2051 10.1016/j.bbmt.2015.09.016 26428082

상세보기
10. Sobh M. Michallet M. Gahrton G. Iacobelli S. van Biezen A. Schonland S. Petersen E. Schaap N. Bonifazi F. Volin L. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: Trends and outcomes over 25 years. A study by the EBMT chronic malignancies working party Leukemia 2016 30 2047 2054 10.1038/leu.2016.101 27118410

상세보기
11. Yin X. Tang L. Fan F. Jiang Q. Sun C. Hu Y. Allogeneic stem-cell transplantation for multiple myeloma: A systematic review and meta-analysis from 2007 to 2017 Cancer Cell Int. 2018 18 62 10.1186/s12935-018-0553-8 29713245

상세보기
12. Waxman A.J. Mink P.J. Devesa S.S. Anderson W.F. Weiss B.M. Kristinsson S.Y. McGlynn K.A. Landgren O. Racial disparities in incidence and outcome in multiple myeloma: A population-based study Blood 2010 116 5501 5506 10.1182/blood-2010-07-298760 20823456

상세보기
13. Kim D.S. Introduction: Health of the health care system in Korea Soc. Work Public Health 2010 25 127 141 10.1080/19371910903070333 20391257

상세보기
14. Glucksberg H. Storb R. Fefer A. Buckner C.D. Neiman P.E. Clift R.A. Lerner K.G. Thomas E.D. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors Transplantation 1974 18 295 304 10.1097/00007890-197410000-00001 4153799

상세보기
15. Jagasia M.H. Greinix H.T. Arora M. Williams K.M. Wolff D. Cowen E.W. Palmer J. Weisdorf D. Treister N.S. Cheng G.S. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report Biol. Blood Marrow Transplant. 2015 21 389 401.e38 10.1016/j.bbmt.2014.12.001 25529383

상세보기
16. Rajkumar S.V. Harousseau J.L. Durie B. Anderson K.C. Dimopoulos M. Kyle R. Blade J. Richardson P. Orlowski R. Siegel D. Consensus recommendations for the uniform reporting of clinical trials: Report of the international myeloma workshop consensus panel 1 Blood 2011 117 4691 4695 10.1182/blood-2010-10-299487 21292775

상세보기
17. Holtan S.G. DeFor T.E. Lazaryan A. Bejanyan N. Arora M. Brunstein C.G. Blazar B.R. MacMillan M.L. Weisdorf D.J. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation Blood 2015 125 1333 1338 10.1182/blood-2014-10-609032 25593335

상세보기
18. Lonial S. Boise L.H. Kaufman J. How I treat high-risk myeloma Blood 2015 126 1536 1543 10.1182/blood-2015-06-653261 26272217

상세보기
19. Pawarode A. Mineishi S. Reddy P. Braun T.M. Khaled Y.A. Choi S.W. Magenau J.M. Harris A.C. Connelly J.A. Kitko C.L. Reducing treatment-related mortality did not improve outcomes of allogeneic myeloablative hematopoietic cell transplantation for high-risk multiple myeloma: A university of michigan prospective series Biol. Blood Marrow Transplant. 2016 22 54 60 10.1016/j.bbmt.2015.07.021 26211984

상세보기
20. Lee C.K. Badros A. Barlogie B. Morris C. Zangari M. Fassas A. van Rhee F. Cottler-Fox M. Jacobson J. Thertulien R. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning Exp. Hematol. 2003 31 73 80 10.1016/S0301-472X(02)01010-X 12543109

상세보기
21. El-Cheikh J. Crocchiolo R. Furst S. Stoppa A.M. Ladaique P. Faucher C. Calmels B. Lemarie C. De Colella J.M. Granata A. Long-Term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma Am. J. Hematol. 2013 88 370 374 10.1002/ajh.23412 23460414

상세보기
22. Pinto V. Bergantim R. Caires H.R. Seca H. Guimaraes J.E. Vasconcelos M.H. Multiple myeloma: Available therapies and causes of drug resistance Cancers 2020 12 407 10.3390/cancers12020407 32050631

상세보기
23. Solimando A.G. Da Via M.C. Cicco S. Leone P. Di Lernia G. Giannico D. Desantis V. Frassanito M.A. Morizio A. Delgado Tascon J. High-Risk multiple myeloma: Integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment J. Clin. Med. 2019 8 997 10.3390/jcm8070997 31323969

상세보기
24. Moreau P. Cavo M. Sonneveld P. Rosinol L. Attal M. Pezzi A. Goldschmidt H. Lahuerta J.J. Marit G. Palumbo A. Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death J. Clin. Oncol. 2014 32 2173 2180 10.1200/jco.2013.53.0329 24888806

상세보기
25. Gerull S. Goerner M. Benner A. Hegenbart U. Klein U. Schaefer H. Goldschmidt H. Ho A.D. Long-Term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma Bone Marrow Transplant. 2005 36 963 969 10.1038/sj.bmt.1705161 16184182

상세보기
26. Dhakal B. D’Souza A. Martens M. Kapke J. Harrington A.M. Pasquini M. Saber W. Drobyski W.R. Zhang M.J. Hamadani M. Allogeneic hematopoietic cell transplantation in multiple myeloma: Impact of disease risk and post allograft minimal residual disease on survival Clin. Lymphoma Myeloma Leuk. 2016 16 379 386 10.1016/j.clml.2016.03.001 27160644

상세보기
27. Greil C. Engelhardt M. Ihorst G. Schoeller K. Bertz H. Marks R. Zeiser R. Duyster J. Einsele H. Finke J. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life Haematologica 2019 104 370 379 10.3324/haematol.2018.200881 30237266

상세보기
28. Franssen L.E. Raymakers R.A. Buijs A. Schmitz M.F. van Dorp S. Mutis T. Lokhorst H.M. van de Donk N.W. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: Long-Term follow-up in a single institution Eur. J. Haematol. 2016 97 479 488 10.1111/ejh.12758 27028304

상세보기
29. Bjorkstrand B. Iacobelli S. Hegenbart U. Gruber A. Greinix H. Volin L. Narni F. Musto P. Beksac M. Bosi A. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-Term follow-up J. Clin. Oncol. 2011 29 3016 3022 10.1200/JCO.2010.32.7312 21730266

상세보기
30. Park S.S. Kim K. Kim S.J. Lee J.H. Yoon S.S. Mun Y.C. Lee J.J. Eom H.S. Kim J.S. Min C.K. A Phase I/II, Open-Label, Prospective, multicenter study to evaluate the efficacy and safety of lower doses of bortezomib plus busulfan and melphalan as a conditioning regimen in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation: The KMM103 study Biol. Blood Marrow Transplant. 2019 25 1312 1319 10.1016/j.bbmt.2019.03.016 30910603

상세보기
31. Rajkumar S.V. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management Am. J. Hematol. 2016 91 719 734 10.1002/ajh.24402 27291302

상세보기
32. Bensinger W.I. Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Best Pract. Res. Clin. Haematol. 2007 20 783 795 10.1016/j.beha.2007.09.007 18070719

상세보기
33. Gahrton G. Svensson H. Cavo M. Apperly J. Bacigalupo A. Bjorkstrand B. Blade J. Cornelissen J. de Laurenzi A. Facon T. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983？93 and 1994？8 at European Group for Blood and Marrow Transplantation centres Br. J. Haematol. 2001 113 209 216 10.1046/j.1365-2141.2001.02726.x 11360893

상세보기
34. Sahebi F. Shen Y. Thomas S.H. Rincon A. Murata-Collins J. Palmer J. Krishnan A.Y. Karanes C. Htut M. Somlo G. Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: A long-term follow-up study Br. J. Haematol. 2013 160 199 206 10.1111/bjh.12123 23151215

상세보기

LOADING...

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증